- Oops!Something went wrong.Please try again later.
Doximity shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 74 to 85.
You don't have to settle for boring old dividend stocks to fit that purpose. Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). Abbott Laboratories is a robust healthcare business that makes for an ideal set-and-forget investment.
When you buy a stock, the worst thing that can happen is that you lose 100% of your investment. Of course, that's not a great outcome, but the downside is smaller than the upside. In other words, when you buy a stock, the upside doesn't stop at 100%.
ARK Invest is adding to some of Cathie Wood's favorite positions even when they're falling out of favor.
The market has written off these two high-quality stocks, but both could complement an income investor's portfolio.
Shares of satellite communications company Globalstar (NYSEMKT: GSAT) crashed 21% yesterday after it became apparent that Apple's (NASDAQ: AAPL) new iPhone 13 will in fact not enable users to call each other via satellite. In the absence of any actual "good" news to explain the stock's bounce higher, I can only surmise that what we're looking at today is a "dead cat bounce." The way they would have placed that bet would have been by shorting Globalstar stock (i.e., selling stock they did not own, in hopes of buying it back later, cheaper, and returning the shares to their rightful owners).
Wynn Resorts and Las Vegas Sands have tumbled. Analysts say the firms may face tougher regulations but will survive, and that their shares could be bargains.
Read more to find out why we think Novavax (NASDAQ: NVAX), Sorrento Therapeutics (NASDAQ: SRNE), and InMode (NASDAQ: INMD) will close out 2021 with a bang. Taylor Carmichael (Novavax): Novavax stock has already doubled this year, running from $112 back in January to $233 this week. Right now, Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation.
Cell biology specialist Berkeley Lights (NASDAQ: BLI) was getting slammed by investors on Wednesday, following a scathing tweet from an institutional short-seller. A firm called Scorpion Capital, which describes itself as focused on "activist short selling" of businesses it considers dubious, thrashed Berkeley Lights in a tweet thread published Wednesday morning. In the thread, Scorpion Capital forcefully accused the company of "Fleecing Customers And IPO Bagholders With A $2 [million] Black Box That's A Clunker."
The most far-reaching part of Democrats' proposal within the $3.5 trillion reconciliation package is the requirement for many businesses to offer a retirement plan for their workers.
More news today from Chinese officials has investors fearing what might be next for U.S.-traded Chinese companies.
Sundial Growers Inc. (NASDAQ: SNDL) ("Sundial" or the "Company"), a Canadian licensed producer that crafts premium cannabis, has launched Caviar Cones, its newest product innovation, under the award-winning Top Leaf brand. The Forbidden Lemon Caviar Cones will be the first caviar cone product to hit the Canadian market. This launch reinforces Sundial's focused innovation pipeline around premium inhalables in the Canadian cannabis market.
Here are two ways to play the energy space -- one that's focusing on the here and now, and another that's looking toward a very different future.
What happened Shares of computing solution and Bitcoin (CRYPTO: BTC) mining supplier Canaan (NASDAQ: CAN) fell as much as 13.8% in trading on Wednesday after the company announced second-quarter 2021 financial results.
With the Nasdaq Composite still flirting with its all-time highs, investors might be surprised to find some technology stocks are actually trading at relative bargain valuations. Zendesk (NYSE: ZEN), Teladoc (NYSE: TDOC), and Zoom Video(NASDAQ: ZM) all have great products and sound strategies that should make them winners over the long term. Right now, though, they are in Wall Street's doghouse.
Shares of Alibaba Group Holding (BABA), the Chinese e-commerce giant, have fallen for three days straight. Indeed, if you pull back the camera a bit and widen the lens, they've been falling much longer than that -- down 50% since peaking last October, when the coronavirus was still ravaging retailers all around the globe, and only China seemed to have any semblance of control over the pandemic. And that's why it's such a crying shame that "China" is itself the reason Alibaba stock has been sinki
If this is because business prospects have worsened, the dividend is at risk. Based on these stocks' yields, you should just about double your money on the dividends alone, as long as you reinvest them at the same rate. Add in the potential for stock price appreciation, and these high-risk stocks could provide you with a nice reward in a decade.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
WASHINGTON (Reuters) -Federal Reserve Chair Jerome Powell has ordered a sweeping review of the ethics rules governing financial holdings and dealings by senior officials at the U.S. central bank, a Fed spokesperson said on Thursday. Powell ordered the review late last week, the spokesperson said in an emailed statement, following recent reports that two of the Fed system's 12 regional reserve bank presidents had been active investors during 2020, a notably volatile year for asset prices as the country battled the COVID-19 pandemic. "Because the trust of the American people is essential for the Federal Reserve to effectively carry out our important mission, Chair Powell late last week directed Board staff to take a fresh and comprehensive look at the ethics rules around permissible financial holdings and activities by senior Fed officials," the statement said.
Ben Lee, IGamiX Managing Partner, joins Yahoo Finance Live to discuss the latest regulatory concerns facing the Macau gaming industry, sending casino shares lower.
Boston Beer's (NYSE: SAM) ride on the hard seltzer growth train is over, and the end is uglier than many people imagined. Having already admitted in July it badly misjudged the alcoholic beverage's popularity, Boston Beer has been forced to concede again that demand is even worse than it predicted, and management withdrew its guidance for the rest of the year as a result. Hard seltzer's slowdown caught everyone by surprise as 2021 was supposed to be another year of rapid growth, but the shock waves from the sudden drop in demand are still being felt.